MS
Morgan Stanley
MS has the edge over OZK overall, supported by stronger fundamentals and stronger modeled upside.
OZK
Bank OZK
OZK trails on the overall score without a compensating advantage in the available component scores.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
OZK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
OZK's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like OZK.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
OZK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.3x | $44.10 | -13% |
| Current | 8.3x | $50.45 | — |
| Fair | 8.4x | $50.57 | +0.2% |
| Forward | 8.4x | $50.45 | — |
| Expensive | 11x | $67.55 | +34% |
Historical ranges are pointers, not guarantees.
OZK has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over OZK on the outlook, with more favorable valuation and earnings expectations.
OZK Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Weakening | |
| Limited | |
| High |
Analysts expect OZK's profitability to weaken, with its earnings and revenue holding steady.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over OZK on earnings, with more consistent year-over-year improvement.
OZK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.01 | -0.7% |
| Q2 2026 | $6.05 | -1.8% |
| Q1 2026 | $6.14 | +0.7% |
| Q4 2025 | $6.17 | +0.5% |
| Q3 2025 | $6.20 | +2% |
| Q2 2025 | $6.16 | +2.3% |
| Q1 2025 | $6.10 | +2.2% |
| Q4 2024 | $6.14 | +4.6% |
| Q3 2024 | $6.08 | +6.5% |
OZK earned $6.05 per share over the past year, down 1.8% from the year before.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over OZK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over OZK on profitability, with a higher operating margin.
OZK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $672.9M | -3.8% |
| Q1 2026 | $661.5M | -1.3% |
| Q4 2025 | $704.6M | +1.3% |
| Q3 2025 | $731.1M | +2.2% |
| Q2 2025 | $699.6M | +0.4% |
| Q1 2025 | $670.5M | +0.6% |
| Q4 2024 | $695.6M | +7% |
| Q3 2024 | $715.7M | +21% |
OZK's revenue grew through 2024 and has held roughly level since: $673M last quarter, down 3.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 32% | -2.5 points |
| Q1 2026 | 32% | -1.4 points |
| Q4 2025 | 32% | -1.4 points |
| Q3 2025 | 33% | +0.1 points |
| Q2 2025 | 34% | +1.2 points |
| Q1 2025 | 33% | -1.1 points |
| Q4 2024 | 34% | +0.2 points |
| Q3 2024 | 33% | -4.2 points |
OZK's operating margin was 32% last quarter, down 2.5 points from the same quarter a year ago, near the bottom of its range since 2019.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
OZK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $189M | +48% |
| Q1 2026 | $212.1M | -12% |
| Q4 2025 | $175.3M | +45% |
| Q3 2025 | $186M | -28% |
| Q2 2025 | $128.1M | -5.4% |
| Q1 2025 | $242.3M | +8% |
| Q4 2024 | $121M | -35% |
| Q3 2024 | $258M | -3.3% |
OZK has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has 1.6B diluted shares, down 1.5% from a year ago.
OZK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.1% | -1.2M shares |
| 1 year | -3.6% | -4.1M shares |
| 3 years | -4% | -4.6M shares |
| 5 years | -16% | -20.6M shares |
| Available history | -15% | -19.3M shares |
OZK has the edge over MS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $15.5M |
| Q1 2026 | $60M |
| Q4 2025 | $93.7M |
| Q3 2025 | — |
| Q2 2025 | $50.8M |
| Q1 2025 | $7.1M |
| Q4 2024 | — |
| Q3 2024 | $462,000 |
OZK spent $169M buying back its own shares over the past year, up 190% from the year before.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
OZK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -0.9x | Net Cash |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
| Q3 2024 | -2.1x | Net Cash |
OZK has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
OZK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.2 | Neutral |
| Stochastic | 75.3 | Neutral |
OZK's weekly RSI is 54 (neutral) and its Stochastic is 75 (neutral).
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
OZK PE vs Financial Services Sector
| Metric | OZK | Sector median | Relative |
|---|---|---|---|
| PE | 8.3x | 13x | 36% below |
| PE % | 49 | 63 | 14 pts below |
OZK has the edge over MS on valuation relative to its sector.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
OZK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $48.3 | 4.4% above |
| 20 week MA | $49.5 | 1.8% above |
| 50 week MA | $48.5 | 4% above |
| 100 week MA | $47.8 | 5.6% above |
| 200 week MA | $44.9 | 12% above |
OZK has the edge over MS on trend strength, trading above more of its moving averages.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.
OZK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.8 | $31.1 | +1% |
| 2021 | $31.1 | $45.4 | +46% |
| 2022 | $45.4 | $40.3 | -11% |
| 2023 | $40.3 | $49.8 | +24% |
| 2024 | $49.8 | $44.6 | -11% |
| 2025 | $44.6 | $47.2 | +5.8% |
| 2026 YTD | $47.2 | $50.5 | +7% |
OZK has the edge over MS on returns for 2026, with the stronger performance.